Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Pharmacological management of cardiovascular disease in patients with rheumatoid arthritis

  • Chapter
  • First Online:
Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis

  • 851 Accesses

Abstract

Although there is a large body of knowledge on the increased cardiovascular disease (CVD) risk in rheumatoid arthritis (RA), there is a lack of clinical evidence on management of the increased risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Perk J, De BG, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012;223:1-68.

    Article  CAS  PubMed  Google Scholar 

  2. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.

    Article  CAS  PubMed  Google Scholar 

  3. Corrales A, Gonzalez-Juanatey C, Peiro ME, Blanco R, Llorca J, Gonzalez-Gay MA. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 2014;73:722-727.

    Article  PubMed  Google Scholar 

  4. Nurmohamed M, EULAR task force. EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases. Eular Recommendation Update on Cardiovascular Disease in RA. Ann Rheum Dis. 2015;74:9.

    Article  Google Scholar 

  5. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167-2172.

    PubMed  Google Scholar 

  6. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int. 1992;37:S34-S37.

    CAS  Google Scholar 

  7. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011;19:184-191.

    Article  PubMed  Google Scholar 

  8. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;CD007893.

    Google Scholar 

  9. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis–results of a prospective non-interventional study. Clin Rheumatol. 2010; 29(8):913-920.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Roman MJ, Moeller E, Davis A, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med .2006;144:249-256.

    Article  PubMed  Google Scholar 

  11. Cypiene A, Dadoniene J, Rugiene R, Ryliskyte L, Kovaite M, Petrulioniene Z et al. The influence of mean blood pressure on arterial stiffening and endothelial dysfunction in women with rheumatoid arthritis and systemic lupus erythematosus. Medicina (Kaunas). 2010;46:522-530.

    PubMed  Google Scholar 

  12. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357.

    Article  CAS  PubMed  Google Scholar 

  13. Catapano AL, Chapman J, Wiklund O, Taskinen MR. The new joint EAS/ESC guidelines for the management of dyslipidaemias. Atherosclerosis. 2011; 217:1.

    PubMed  Google Scholar 

  14. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670-1681.

    Article  CAS  PubMed  Google Scholar 

  15. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781.

    Article  CAS  PubMed  Google Scholar 

  17. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.

    Article  CAS  PubMed  Google Scholar 

  18. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative metaanalysis of randomised statin trials. Lancet. 2010;375:735-742.

    Article  CAS  PubMed  Google Scholar 

  19. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-571.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-122.

    Article  CAS  PubMed  Google Scholar 

  21. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol. 2008;52:1141-1147.

    Article  CAS  PubMed  Google Scholar 

  22. Akkara Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Crowson CS. Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol. 2013;40:1082-1088.

    Article  PubMed  Google Scholar 

  23. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8:301-326.

    Article  CAS  PubMed  Google Scholar 

  24. Soubrier M, Zerkak D, Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol. 2006;33:1766-1769.

    CAS  PubMed  Google Scholar 

  25. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010;69:683-688.

    Article  CAS  PubMed  Google Scholar 

  26. Lindhardsen J, Ahlehoff O, Gislason GH, et al. Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2012;71:1496-1501.

    Article  CAS  PubMed  Google Scholar 

  27. De Vera MA, Choi H, Abrahamowicz M, Kopec J, Lacaille D. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2012;64:809-816.

    Article  PubMed  Google Scholar 

  28. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004; 363:2015-2021.

    Article  CAS  PubMed  Google Scholar 

  29. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol. 2011;38:229-235.

    Article  CAS  PubMed  Google Scholar 

  30. Ikdahl E, Hisdal J, Rollefstad S, et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther. 2015;17:279.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1571-1575.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007;34:1459-1464.

    CAS  PubMed  Google Scholar 

  33. Bansback N, Ara R, Ward S, Anis A, Choi HK. Statin therapy in rheumatoid arthritis: a costeffectiveness and value-of-information analysis. Pharmacoeconomics. 2009;27:25-37.

    Article  PubMed  Google Scholar 

  34. Kitas GD, Nightingale P, Armitage J, et al. Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2015;67.

    Google Scholar 

  35. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012;64:2836-2846.

    Article  CAS  PubMed  Google Scholar 

  36. Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann Rheum Dis. 2013;72:1968-1974.

    Article  CAS  PubMed  Google Scholar 

  37. Kotseva K, Wood D, De BD, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-648.

    Article  PubMed  Google Scholar 

  38. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.

    Article  CAS  PubMed  Google Scholar 

  39. Peters MJ, Voskuyl AE, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract. 2010;64:1440-1443.

    Article  CAS  PubMed  Google Scholar 

  40. Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis. 2010;69:1996-2001.

    Article  CAS  PubMed  Google Scholar 

  41. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68:460-469.

    Article  CAS  PubMed  Google Scholar 

  42. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957-2963.

    Article  PubMed  Google Scholar 

  43. Toms TE, Panoulas VF, Douglas KM, et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? Angiology. 2011;62:167-175.

    Article  CAS  PubMed  Google Scholar 

  44. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Rollefstad S, Ikdahl E, Hisdal J, et al. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Ann Rheum Dis. 2015;74:1544-1550.

    Article  CAS  PubMed  Google Scholar 

  46. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.

    Article  CAS  PubMed  Google Scholar 

  47. Myasoedova E, Gabriel SE, Green AB, Matteson EL, Crowson CS. Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study. Arthritis Care Res (Hoboken). 2013;65:1592-1599.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2009;2:173-181.

    Article  CAS  PubMed  Google Scholar 

  49. Rollefstad S, Ikdahl E, Hisdal J, et al. Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. Arthritis Rheumatol. 2015;67:1718-1728.

    Article  CAS  PubMed  Google Scholar 

  50. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48.

    Google Scholar 

  51. Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18-24.

    Article  CAS  PubMed  Google Scholar 

  52. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261-263.

    PubMed  Google Scholar 

  53. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209-216.

    Article  CAS  PubMed  Google Scholar 

  54. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825.

    Article  CAS  PubMed  Google Scholar 

  55. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35:1782-1791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.

    Article  CAS  PubMed  Google Scholar 

  57. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53:2143-2154.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49:295-307.

    Article  CAS  PubMed  Google Scholar 

  59. van Dongen H, van AJ, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424-1432.

    Google Scholar 

  60. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576-582.

    Article  PubMed  Google Scholar 

  61. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med. 2002;113:188-193.

    Article  CAS  PubMed  Google Scholar 

  62. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther. 2006;8:R82.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. 2002;4:R12.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci. 2010;1193:153-159.

    Article  CAS  PubMed  Google Scholar 

  65. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495-1498.

    Article  PubMed  Google Scholar 

  66. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518-531.

    Article  CAS  PubMed  Google Scholar 

  67. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and metaanalysis. Ann Rheum Dis. 2015;74:480-489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNFalpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens. 2012;25:644-650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73:124-131.

    Article  CAS  PubMed  Google Scholar 

  70. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905-2912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.

    Article  CAS  PubMed  Google Scholar 

  72. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628-1636.

    Article  PubMed  Google Scholar 

  73. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302-1308.

    CAS  PubMed  Google Scholar 

  74. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-779.

    Article  CAS  PubMed  Google Scholar 

  77. Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2013 [Epub ahead of print]; doi:10.1136/annrheumdis-2012-203137.

  78. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and diseasemodifying drug treatment. Arch Intern Med. 1987;147:1917-1920.

    Article  CAS  PubMed  Google Scholar 

  79. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53:528-535.

    Article  CAS  PubMed  Google Scholar 

  80. Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 1976;271:202-210.

    Article  CAS  PubMed  Google Scholar 

  81. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859-865.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.

    Article  PubMed  Google Scholar 

  83. Davis JM, III, Maradit KH, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;56:820-830.

    Article  CAS  PubMed  Google Scholar 

  84. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study. BMJ. 2012;345:e4928.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5:77-85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013;2:77-83.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diakonhjemmet Hospital, Oslo, Norway

    Silvia Rollefstad, Eirik Ikdahl & Anne Grete Semb

Authors
  1. Silvia Rollefstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eirik Ikdahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Grete Semb
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Preventive Cardio-Rheuma Clinic, Diakonhjemmet Hospital, Oslo, Oslo, Norway

    Anne Grete Semb

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Rollefstad, S., Ikdahl, E., Semb, A.G. (2017). Pharmacological management of cardiovascular disease in patients with rheumatoid arthritis. In: Semb, A. (eds) Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis. Adis, Cham. https://doi.org/10.1007/978-3-319-26782-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26782-1_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26780-7

  • Online ISBN: 978-3-319-26782-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation